Cellectar Biosciences, Inc.
CLRB
$4.77
$0.06831.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -42.63% | -39.47% | 35.86% | 229.33% | 194.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -55.94% | -46.67% | 1.57% | 41.58% | 65.22% |
| Operating Income | 55.94% | 46.67% | -1.57% | -41.58% | -65.22% |
| Income Before Tax | -492.55% | 75.21% | 71.17% | 16.30% | 90.97% |
| Income Tax Expenses | -- | -- | 210.00% | -- | -- |
| Earnings from Continuing Operations | -492.55% | 75.21% | 70.11% | 16.30% | 90.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -492.55% | 75.21% | 70.11% | 16.30% | 90.97% |
| EBIT | 55.94% | 46.67% | -1.57% | -41.58% | -65.22% |
| EBITDA | 56.14% | 46.74% | -1.59% | -41.47% | -65.20% |
| EPS Basic | -339.78% | 84.21% | 89.27% | 75.94% | 97.16% |
| Normalized Basic EPS | -339.75% | 84.21% | 89.65% | 75.94% | 97.16% |
| EPS Diluted | 37.54% | 84.21% | 89.34% | 73.91% | 79.98% |
| Normalized Diluted EPS | -359.81% | 84.21% | 89.65% | 76.21% | 97.28% |
| Average Basic Shares Outstanding | 34.74% | 57.02% | 178.60% | 247.80% | 218.06% |
| Average Diluted Shares Outstanding | 28.89% | 57.02% | 178.60% | 251.86% | 232.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |